The migraine
market is saturated with generic drugs, and the remaining branded products
already on the market are expected to lose exclusivity during the next few
years, with the exception of Botox for chronic migraine, which is expected to
maintain its leading position in terms of sales.
However,
reformulations of mature products as well as new classes of therapies are
anticipated to launch during the forecast period and these will contribute to
the market growth. By 2023, the migraine market will grow to $3.7 billion at a
compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate
the market as a result of higher drug prices and a large migraine population.
Some of the new treatments are expected to target the key unmet needs but
opportunities will remain for further treatment choices especially drugs that
will offer an improved safety and side-effects profile.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/ergot-alkaloids-migraine-forecast-and-market-analysis-to-2023
The Ergot
Alkaloids were the very first anti-migraine-specific therapy class to reach the
market. The first pure ergot alkaloid was isolated in 1920, but only in 1925
was ergotamine used to successfully treat a case of severe and intractable
migraine via subcutaneous injection (Rothlin, 1955; Stoll, 1965). Over the
following decades, ergotamine's use as a migraine treatment was investigated by
various researchers and its potent vasoconstriction properties reinforced the
belief that migraine had a vascular origin.
Scope
- Overview
of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive landscape.
- Detailed
information on Ergot Alkaloids including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales
forecast for Ergot Alkaloids for the top two countries from 2012 to 2023.
- Sales
information covered for the US and Japan.
Reasons to buy
- Understand
and capitalize by identifying products that are most likely to ensure a robust
return
- Stay ahead
of the competition by understanding the changing competitive landscape for
Migraine
-
Effectively plan your M&A and partnership strategies by identifying drugs
with the most promising sales potential
- Make more
informed business decisions from insightful and in-depth analysis of Ergot
Alkaloids performance
- Obtain
sales forecast for Ergot Alkaloids from 2012-2023 in the top two countries (the
US and Japan)
About Us
Radiant Insights is a platform for companies
looking to meet their market research and business intelligence requirements.
We assist and facilitate organizations and individuals procure market research
reports, helping them in the decision making process. We have a comprehensive
collection of reports, covering over 40 key industries and a host of micro
markets. In addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For more
information visit: Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog
URL: http://www.esorics2010.org/
No comments:
Post a Comment